cytarabine has been researched along with Cardiac Toxicity in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fortin, MC; Grammatopoulos, TN; LaCroix, AS; Manca, D; Tan, L; Wang, Q | 1 |
| Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB | 1 |
| Allen, K; Castellino, SM; Cooper, TM; Keller, FG; Metts, JL; Minson, KA; Monroe, C; Sabnis, HS; Woods, WG | 1 |
1 trial(s) available for cytarabine and Cardiac Toxicity
| Article | Year |
|---|---|
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
2 other study(ies) available for cytarabine and Cardiac Toxicity
| Article | Year |
|---|---|
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Cytarabine; Daunorubicin; Drug Combinations; Humans; Induced Pluripotent Stem Cells; Liposomes; Myocytes, Cardiac; Topoisomerase II Inhibitors | 2023 |
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |